论文部分内容阅读
鲁拉西酮为一新型非典型抗精神病药,属于苯并异噻唑衍生物,为多巴胺D_2和5-羟色胺2A(5-HT_(2A))受体拮抗剂。2010年10月28日美国食品和药物管理局批准鲁拉西酮上市,其商品名为Latuda,用于治疗成人精神分裂症。鲁拉西酮的有效剂量范围为40～120mg·d~(-1),推荐起始剂量为40mg·d~(-1),一般最大推荐剂量为80mg·d~(-1),应与食物同时服用。鲁拉西酮常见不良反应有嗜睡、静坐不能、恶心、帕金森病以及焦虑。本文对鲁拉西酮的药理作用、药动学、药物相互作用、临床评价和安全性等进行综述。
Lubrazilone is a new class of atypical antipsychotics and belongs to benzisothiazole derivatives, which are dopamine D 2 and serotonin 2A (5-HT_ (2A)) receptor antagonists. October 28, 2010 The US Food and Drug Administration approved the listing of lurasidone under the trade name Latuda for the treatment of schizophrenia in adults. The effective dose range of brucirone is 40 ~ 120 mg · d ~ (-1), the recommended initial dose is 40 mg · d ~ (-1), the maximum recommended dose is 80 mg · d ~ (-1) Take the food at the same time. Common side effects of lurasidone are lethargy, sedation, nausea, Parkinson’s disease and anxiety. This article reviews the pharmacological effects of lurasidone, pharmacokinetics, drug interactions, clinical evaluation and safety.